Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial

Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial

Abstract GT103 is a first-in-class, fully human, IgG3 monoclonal antibody targeting complement factor H that kills tumor cells and promotes anti-cancer immunity in preclinical models. We conducted a first-in-human phase 1b study dose escalation trial of GT103 in refractory non-small cell lung cancer...

Full description

Saved in:
Bibliographic Details
Main Authors: Jeffrey M. Clarke, George R. Simon, Hirva Mamdani, Lin Gu, James E. Herndon, Thomas E. Stinchcombe, Neal Ready, Jeffrey Crawford, Guru Sonpavde, Stephen Balevic, Andrew B. Nixon, Michael Campa, Elizabeth B. Gottlin, Huihua Li, Ruchi Saxena, You Wen He, Scott Antonia, Edward F. Patz
Format: Article
Language:English
Published: Nature Portfolio 2025-01-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-024-55092-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41467-024-55092-2

Similar Items